Cibisatamab

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameCibisatamab

Drug Alias NameCEA-TCBRG-7802RO-6958688CEA-CD3 TCB

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionCarcinoembryonic antigen inhibitorsT cell surface glycoprotein CD3 inhibitors

TargetsT cell surface glycoprotein CD3Carcinoembryonic antigen

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesNetherlands +[11]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ltd

China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A